Nuwellis Inc. Prices $6 Million Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Offering Overview: Nuwellis, Inc. has announced a public offering of 20 million shares of common stock at a price of $0.30 per share, expected to raise approximately $6 million, which will be utilized to support medical technology solutions for patients with cardiorenal conditions.
- Warrant Details: The accompanying Series C and Series D Warrants have an exercise price of $0.30 and will be exercisable for five years following stockholder approval, indicating the company's focus on maintaining flexibility in future financing.
- Private Placement Transactions: The company also engaged in private placement transactions with existing warrant holders to reduce the exercise price of previously issued warrants to $0.30, enhancing the flexibility of its capital structure.
- Regulatory Compliance: This offering is conducted under a registration statement with the U.S. Securities and Exchange Commission, ensuring compliance and paving the way for future market opportunities, reflecting the company's commitment to transparency and regulatory adherence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUWE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUWE
Wall Street analysts forecast NUWE stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 0.431
Low
5.50
Averages
5.50
High
5.50
Current: 0.431
Low
5.50
Averages
5.50
High
5.50
No data
About NUWE
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuwellis Inc. Prices $6 Million Public Offering of Common Stock
- Offering Overview: Nuwellis, Inc. has announced a public offering of 20 million shares of common stock at a price of $0.30 per share, expected to raise approximately $6 million, which will be utilized to support medical technology solutions for patients with cardiorenal conditions.
- Warrant Details: The accompanying Series C and Series D Warrants have an exercise price of $0.30 and will be exercisable for five years following stockholder approval, indicating the company's focus on maintaining flexibility in future financing.
- Private Placement Transactions: The company also engaged in private placement transactions with existing warrant holders to reduce the exercise price of previously issued warrants to $0.30, enhancing the flexibility of its capital structure.
- Regulatory Compliance: This offering is conducted under a registration statement with the U.S. Securities and Exchange Commission, ensuring compliance and paving the way for future market opportunities, reflecting the company's commitment to transparency and regulatory adherence.
See More
Nuwellis, Inc. Prices Public Offering to Raise $6 Million
- Offering Size: Nuwellis, Inc. announced a public offering priced at $0.30 per share, expected to raise approximately $6 million, demonstrating the company's ability to access capital markets effectively.
- Shares and Warrants: The offering includes 20 million shares of common stock and accompanying warrants, along with Series C and D warrants allowing the purchase of up to 60 million and 20 million shares respectively, enhancing investor participation opportunities.
- Exercise Price and Conditions: All warrants have an exercise price of $0.30 and become exercisable upon stockholder approval and the effectiveness of a reverse stock split, which may impact future shareholder structure and stock price performance.
- Private Transactions: Nuwellis also entered into concurrent private transactions with existing warrant holders to reduce the exercise price of previously issued warrants to $0.30, aimed at improving market liquidity and boosting investor confidence.
See More
Nuwellis Expands Aquadex Labeling to Pediatric Patients
- Successful FDA Meeting: Nuwellis has successfully completed a pre-submission meeting with the FDA regarding the proposed label expansion of the Aquadex SmartFlow® System to pediatric patients weighing 5 kg and above, indicating positive progress in addressing market needs.
- Clinical Demand Response: The real-time monitoring capability of the Aquadex system for fluid management in low-weight pediatric patients provides crucial support for clinical decision-making, which is expected to significantly enhance treatment safety and efficacy for this patient group.
- Clear Regulatory Strategy: Constructive feedback obtained during the meeting clarifies the pathway for Nuwellis's 510(k) submission, supported by targeted bench testing and clinical evidence, thereby strengthening the company's competitive position in this high-need patient population.
- Significant Market Potential: Nuwellis anticipates submitting to the FDA by the end of 2026, aiming to address fluid overload issues in low-weight pediatric patients, further expanding its influence in the rapidly growing pediatric healthcare market.
See More
Nuwellis Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Performance: Nuwellis reported a Q1 GAAP EPS of -$2.09, missing expectations by $1.09, indicating ongoing challenges in achieving profitability.
- Revenue Growth: The company achieved revenue of $2.4 million, a 26.3% year-over-year increase, beating market expectations by $0.31 million, reflecting strong product demand and market performance.
- Gross Margin Improvement: Gross margin improved to 70.1%, driven by successful pricing strategies, optimized product mix, and a transition to contract manufacturing, enhancing the company's profitability.
- Financial Health: As of March 31, 2026, the company reported no debt and approximately $2.2 million in cash, cash equivalents, and restricted cash, indicating strong liquidity and financial stability.
See More
Nuwellis Showcases New Research at International Heart and Lung Transplantation Conference
- Research Presentation: At the 2026 International Society for Heart and Lung Transplantation meeting, the University of Iowa showcased a case study on using ultrafiltration to treat pediatric heart failure, emphasizing its significance in managing complex pediatric cardiorenal patients, which may drive standardization in clinical practice.
- Clinical Application Potential: The case study demonstrated that Aquadex ultrafiltration therapy effectively managed fluid overload in patients with chemotherapy-induced dilated cardiomyopathy, improving pre-operative clinical status and enhancing post-transplant outcomes, indicating its potential in pediatric settings.
- Technology Promotion Strategy: Nuwellis CEO John Erb stated that the company will continue collaborating with practitioners to promote the adoption of Aquadex for pediatric indications, addressing fluid management challenges and enhancing patient care quality.
- Industry Exchange Platform: The ISHLT conference provided a vital opportunity for clinicians and researchers to share emerging data and engage in scientific dialogue, with Nuwellis' participation further solidifying its leadership position in heart and lung disease treatment.
See More
Nuwellis Receives Patent Allowance for Dual-Lumen Catheter
- Patent Progress: Nuwellis announced it received a Notice of Allowance from the USPTO for its dual-lumen catheter used in ultrafiltration therapy, aimed at improving blood flow and reducing treatment complications, which is expected to enhance its product lineup.
- Enhanced Design Flexibility: The catheter features an adjustable, flexible design that allows doctors to customize it during treatment, ensuring smoother usage and improved treatment outcomes across various patients.
- Market Expansion Potential: Once the patent is officially approved, it is anticipated to support Nuwellis in promoting ultrafiltration therapy in hospitals and outpatient settings, thereby expanding market share and enhancing competitive positioning.
- Stock Price Reaction: Despite the positive patent news, Nuwellis' stock is trading approximately 3% lower at around $1.13, reflecting market caution regarding its future growth potential.
See More
Nuwellis Inc. Prices $6 Million Public Offering of Common Stock
- Offering Overview: Nuwellis, Inc. has announced a public offering of 20 million shares of common stock at a price of $0.30 per share, expected to raise approximately $6 million, which will be utilized to support medical technology solutions for patients with cardiorenal conditions.
- Warrant Details: The accompanying Series C and Series D Warrants have an exercise price of $0.30 and will be exercisable for five years following stockholder approval, indicating the company's focus on maintaining flexibility in future financing.
- Private Placement Transactions: The company also engaged in private placement transactions with existing warrant holders to reduce the exercise price of previously issued warrants to $0.30, enhancing the flexibility of its capital structure.
- Regulatory Compliance: This offering is conducted under a registration statement with the U.S. Securities and Exchange Commission, ensuring compliance and paving the way for future market opportunities, reflecting the company's commitment to transparency and regulatory adherence.
See More
Nuwellis, Inc. Prices Public Offering to Raise $6 Million
- Offering Size: Nuwellis, Inc. announced a public offering priced at $0.30 per share, expected to raise approximately $6 million, demonstrating the company's ability to access capital markets effectively.
- Shares and Warrants: The offering includes 20 million shares of common stock and accompanying warrants, along with Series C and D warrants allowing the purchase of up to 60 million and 20 million shares respectively, enhancing investor participation opportunities.
- Exercise Price and Conditions: All warrants have an exercise price of $0.30 and become exercisable upon stockholder approval and the effectiveness of a reverse stock split, which may impact future shareholder structure and stock price performance.
- Private Transactions: Nuwellis also entered into concurrent private transactions with existing warrant holders to reduce the exercise price of previously issued warrants to $0.30, aimed at improving market liquidity and boosting investor confidence.
See More
Nuwellis Expands Aquadex Labeling to Pediatric Patients
- Successful FDA Meeting: Nuwellis has successfully completed a pre-submission meeting with the FDA regarding the proposed label expansion of the Aquadex SmartFlow® System to pediatric patients weighing 5 kg and above, indicating positive progress in addressing market needs.
- Clinical Demand Response: The real-time monitoring capability of the Aquadex system for fluid management in low-weight pediatric patients provides crucial support for clinical decision-making, which is expected to significantly enhance treatment safety and efficacy for this patient group.
- Clear Regulatory Strategy: Constructive feedback obtained during the meeting clarifies the pathway for Nuwellis's 510(k) submission, supported by targeted bench testing and clinical evidence, thereby strengthening the company's competitive position in this high-need patient population.
- Significant Market Potential: Nuwellis anticipates submitting to the FDA by the end of 2026, aiming to address fluid overload issues in low-weight pediatric patients, further expanding its influence in the rapidly growing pediatric healthcare market.
See More
Nuwellis Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Performance: Nuwellis reported a Q1 GAAP EPS of -$2.09, missing expectations by $1.09, indicating ongoing challenges in achieving profitability.
- Revenue Growth: The company achieved revenue of $2.4 million, a 26.3% year-over-year increase, beating market expectations by $0.31 million, reflecting strong product demand and market performance.
- Gross Margin Improvement: Gross margin improved to 70.1%, driven by successful pricing strategies, optimized product mix, and a transition to contract manufacturing, enhancing the company's profitability.
- Financial Health: As of March 31, 2026, the company reported no debt and approximately $2.2 million in cash, cash equivalents, and restricted cash, indicating strong liquidity and financial stability.
See More
Nuwellis Showcases New Research at International Heart and Lung Transplantation Conference
- Research Presentation: At the 2026 International Society for Heart and Lung Transplantation meeting, the University of Iowa showcased a case study on using ultrafiltration to treat pediatric heart failure, emphasizing its significance in managing complex pediatric cardiorenal patients, which may drive standardization in clinical practice.
- Clinical Application Potential: The case study demonstrated that Aquadex ultrafiltration therapy effectively managed fluid overload in patients with chemotherapy-induced dilated cardiomyopathy, improving pre-operative clinical status and enhancing post-transplant outcomes, indicating its potential in pediatric settings.
- Technology Promotion Strategy: Nuwellis CEO John Erb stated that the company will continue collaborating with practitioners to promote the adoption of Aquadex for pediatric indications, addressing fluid management challenges and enhancing patient care quality.
- Industry Exchange Platform: The ISHLT conference provided a vital opportunity for clinicians and researchers to share emerging data and engage in scientific dialogue, with Nuwellis' participation further solidifying its leadership position in heart and lung disease treatment.
See More
Nuwellis Receives Patent Allowance for Dual-Lumen Catheter
- Patent Progress: Nuwellis announced it received a Notice of Allowance from the USPTO for its dual-lumen catheter used in ultrafiltration therapy, aimed at improving blood flow and reducing treatment complications, which is expected to enhance its product lineup.
- Enhanced Design Flexibility: The catheter features an adjustable, flexible design that allows doctors to customize it during treatment, ensuring smoother usage and improved treatment outcomes across various patients.
- Market Expansion Potential: Once the patent is officially approved, it is anticipated to support Nuwellis in promoting ultrafiltration therapy in hospitals and outpatient settings, thereby expanding market share and enhancing competitive positioning.
- Stock Price Reaction: Despite the positive patent news, Nuwellis' stock is trading approximately 3% lower at around $1.13, reflecting market caution regarding its future growth potential.
See More
